Current Cancer Drug Targets, Volume 10 - Number 7

Bone-Targeted Doxorubicin-Loaded Nanoparticles as a Tool for the Treatment of Skeletal Metastases

, 10(7): 649 - 659

M. Salerno, E. Cenni, C. Fotia, S. Avnet, D. Granchi, F. Castelli, D. Micieli, R. Pignatello, M. Capulli, N. Rucci, A. Angelucci, A. Del Fattore, A. Teti, N. Zini, A. Giunti and N. Baldini

DOI: 10.2174/156800910793605767

Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel

, 10(7): 660 - 669

Z. Khan, N. Khan, A. K. Varma, R. P. Tiwari, S. Mouhamad, G. B.K.S. Prasad and P. S. Bisen

DOI: 10.2174/156800910793605866

The Role of Oxidative Stress and Anti-Oxidant Treatment in Platinum-Induced Peripheral Neurotoxicity

, 10(7): 670 - 682

V. A. Carozzi, P. Marmiroli and G. Cavaletti

DOI: 10.2174/156800910793605820

Is Src a Viable Target for Treating Solid Tumours?

, 10(7): 683 - 694

B. Elsberger, B. Stewart, O. Tatarov and J. Edwards

DOI: 10.2174/156800910793605802

Modular Branched Neurotensin Peptides for Tumor Target Tracing and Receptor-Mediated Therapy: A Proof-of-Concept

, 10(7): 695 - 704

C. Falciani, B. Lelli, J. Brunetti, S. Pileri, A. Cappelli, A. Pini, C. Pagliuca, N. Ravenni, L. Bencini, S. Menichetti, R. Moretti, M. De Prizio, M. Scatizzi and L. Bracci

DOI: 10.2174/156800910793605875

Paclitaxel Efficacy is Increased by Parthenolide via Nuclear Factor- KappaB Pathways in In Vitro and In Vivo Human Non – Small Cell Lung Cancer Models

, 10(7): 705 - 715

Z. W. Gao, D. L. Zhang and C. B. Guo

DOI: 10.2174/156800910793605776

Wnt/β-Catenin/LEF-1 Signaling in Chronic Lymphocytic Leukemia (CLL): A Target for Current and Potential Therapeutic Options

, 10(7): 716 - 727

R. K. Gandhirajan, S. J. Poll-Wolbeck, I. Gehrke and K.-A. Kreuzer

DOI: 10.2174/156800910793605794

New Insights of CTLA-4 into Its Biological Function in Breast Cancer

, 10(7): 728 - 736

H. Mao, L. Zhang, Y. Yang, W. Zuo, Y. Bi, W. Gao, B. Deng, J. Sun, Q. Shao and X. Qu

DOI: 10.2174/156800910793605811

Dynamic Simulations of Pathways Downstream of ERBB-Family, Including Mutations and Treatments: Concordance with Experimental Results

, 10(7): 737 - 757

N. Castagnino, L. Tortolina, A. Balbi, R. Pesenti, R. Montagna, A. Ballestrero, D. Soncini, E. Moran, A. Nencioni and S. Parodi

DOI: 10.2174/156800910793605848

DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy

, 10(7): 758 - 771

K. Chikamori, A. G. Grozav, T. Kozuki, D. Grabowski, R. Ganapathi and M. K. Ganapathi

DOI: 10.2174/156800910793605785

Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer

, 10(7): 772 - 781

C. D'Alterio, C. Consales, M. Polimeno, R. Franco, L. Cindolo, L. Portella, M. Cioffi, R. Calemma, L. Marra, L. Claudio, S. Perdona, S. Pignata, G. Facchini, G. Carteni, N. Longo, L. Pucci, A. Ottaiano, S. Costantini, G. Castello and S. Scala

DOI: 10.2174/156800910793605839

Cancer Therapy By Targeting Hypoxia-Inducible Factor-1

, 10(7): 782 - 796

Y. Li and D. Ye

DOI: 10.2174/156800910793605857

Webmaster Contact:
Copyright © 2018 Bentham Science